|
1
|
Ludwig H, Durie BG, Bolejack V, et al:
Myeloma in patients younger than age 50 years presents with more
favorable features and shows better survival: an analysis of 10,549
patients from the International Myeloma Working Group. Blood.
111:4039–4047. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Raab MS, Podar K, Breitkreutz I,
Richardson PG and Anderson KC: Multiple myeloma. Lancet.
374:324–339. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yeung J and Chang H: Genomic aberrations
and immunohistochemical markers as prognostic indicators in
multiple myeloma. J Clin Pathol. 61:832–836. 2008. View Article : Google Scholar
|
|
4
|
Hanamura I, Stewart JP, Huang Y, et al:
Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias
detected by fluorescence in situ hybridization: incidence increases
from MGUS to relapsed myeloma and is related to prognosis and
disease progression following tandem stem-cell transplantation.
Blood. 108:1724–1732. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fonseca R, Van Wier SA, Chng WJ, et al:
Prognostic value of chromosome 1q21 gain by fluorescent in situ
hybridization and increase CKS1B expression in myeloma. Leukemia.
20:2034–2040. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Avet-Loiseau H, Attal M, Moreau P, et al:
Genetic abnormalities and survival in multiple myeloma: the
experience of the Intergroupe Francophone du Myélome. Blood.
109:3489–3495. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zojer N, Königsberg R, Ackermann J, et al:
Deletion of 13q14 remains an independent adverse prognostic
variable in multiple myeloma despite its frequent detection by
interphase fluorescence in situ hybridization. Blood. 95:1925–1930.
2000.PubMed/NCBI
|
|
8
|
Keats JJ, Reiman T, Maxwell CA, et al: In
multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor
irrespective of FGFR3 expression. Blood. 101:1520–1529. 2003.
View Article : Google Scholar
|
|
9
|
Fonseca R, Blood E, Rue M, et al: Clinical
and biologic implications of recurrent genomic aberrations in
myeloma. Blood. 101:4569–4575. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chang H, Sloan S, Li D, et al: The t(4;14)
is associated with poor prognosis in myeloma patients undergoing
autologous stem cell transplant. Br J Haematol. 125:64–68. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gertz MA, Lacy MQ, Dispenzieri A, et al:
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and
−17p13 in myeloma patients treated with high-dose therapy. Blood.
106:2837–2840. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ross FM, Ibrahim AH, Vilain-Holmes A, et
al; UK Myeloma Forum. Age has a profound effect on the incidence
and significance of chromosome abnormalities in myeloma. Leukemia.
19:1634–1642. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Avet-Loiseau H, Malard F, Campion L, et
al; Intergroupe Francophone du Myélome. Translocation t(14;16) and
multiple myeloma: is it really an independent prognostic factor?
Blood. 117:2009–2011. 2011. View Article : Google Scholar
|
|
14
|
Drach J, Ackermann J, Fritz E, et al:
Presence of a p53 gene deletion in patients with multiple myeloma
predicts for short survival after conventional-dose chemotherapy.
Blood. 92:802–809. 1998.PubMed/NCBI
|
|
15
|
Chang H, Qi C, Yi QL, Reece D and Stewart
AK: p53 gene deletion detected by fluorescence in situ
hybridization is an adverse prognostic factor for patients with
multiple myeloma following autologous stem cell transplantation.
Blood. 105:358–360. 2005. View Article : Google Scholar
|
|
16
|
Avet-Loiseau H, Leleu X, Roussel M, et al:
Bortezomib plus dexamethasone induction improves outcome of
patients with t(4;14) myeloma but not outcome of patients with
del(17p). J Clin Oncol. 28:4630–4634. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chang H, Trieu Y, Qi X, Xu W, Stewart KA
and Reece D: Bortezomib therapy response is independent of
cytogenetic abnormalities in relapsed/refractory multiple myeloma.
Leuk Res. 31:779–782. 2007. View Article : Google Scholar
|
|
18
|
Pineda-Roman M, Zangari M, Haessler J, et
al: Sustained complete remissions in multiple myeloma linked to
bortezomib in total therapy 3: comparison with total therapy 2. Br
J Haematol. 140:625–634. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Grogan TM, Van Camp B and Kyle RA: Plasma
cell neoplasms. World Health Organization Classification of Tumors.
Pathology and Genetics of Tumours of Haematopoietic and Lymphoid
Tissues. Jaffe ES, Harris NL, Stein H and Vardiman JW: IARC Press;
Lyon: pp. 1442001
|
|
20
|
Greipp PR, San Miguel J, Durie BG, et al:
International staging system for multiple myeloma. J Clin Oncol.
23:3412–3420. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Durie BG and Salmon SE: A clinical staging
system for multiple myeloma. Correlation of measured myeloma cell
mass with presenting clinical features, response to treatment, and
survival. Cancer. 36:842–854. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Durie BG, Harousseau JL, Miguel JS, et al;
International Myeloma Working Group. International uniform response
criteria for multiple myeloma. Leukemia. 20:1467–1473. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nemec P, Zemanova Z, Kuglik P, et al;
Czech Myeloma Group. Complex karyotype and translocation t(4;14)
define patients with high-risk newly diagnosed multiple myeloma:
results of CMG2002 trial. Leuk Lymphoma. 53:920–927. 2012.
View Article : Google Scholar
|
|
24
|
Grzasko N, Hus M, Pluta A, et al:
Additional genetic abnormalities significantly worsen poor
prognosis associated with 1q21 amplification in multiple myeloma
patients. Hematol Oncol. 31:41–48. 2013. View Article : Google Scholar
|
|
25
|
Neben K, Jauch A, Bertsch U, et al:
Combining information regarding chromosomal aberrations t(4;14) and
del(17p13) with the International Staging System classification
allows stratification of myeloma patients undergoing autologous
stem cell transplantation. Haematologica. 95:1151–1157. 2010.
View Article : Google Scholar
|
|
26
|
Chang H, Yeung J, Qi C and Xu W: Aberrant
nuclear p53 protein expression detected by immunohistochemistry is
associated with hemizygous p53 deletion and poor survival for
multiple myeloma. Br J Haematol. 138:324–329. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xiong W, Wu X, Starnes S, et al: An
analysis of the clinical and biologic significance of TP53 loss and
the identification of potential novel transcriptional targets of
TP53 in multiple myeloma. Blood. 112:4235–4246. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fonseca R, Debes-Marun CS, Picken EB, et
al: The recurrent IgH translocations are highly associated with
nonhyperdiploid variant multiple myeloma. Blood. 102:2562–2567.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fonseca R, Blood EA, Oken MM, et al:
Myeloma and the t(11;14)(q13;q32): evidence for a biologically
defined unique subset of patients. Blood. 99:3735–3741. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stewart AK and Fonseca R: Prognostic and
therapeutic significance of myeloma genetics and gene expression
profiling. J Clin Oncol. 23:6339–6344. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
San Miguel JF, Schlag R, Khuageva NK, et
al; VISTA Trial Investigators. Bortezomib plus melphalan and
prednisone for initial treatment of multiple myeloma. N Engl J Med.
359:906–917. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Barlogie B, Anaissie E, van Rhee F, et al:
Incorporating bortezomib into upfront treatment for multiple
myeloma: early results of total therapy 3. Br J Haematol.
138:176–185. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shaughnessy JD, Zhou Y, Haessler J, et al:
TP53 deletion is not an adverse feature in multiple myeloma treated
with total therapy 3. Br J Haematol. 147:347–351. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Richardson PG, Xie W, Mitsiades C, et al:
Single-agent bortezomib in previously untreated multiple myeloma:
efficacy, characterization of peripheral neuropathy, and molecular
correlations with response and neuropathy. J Clin Oncol.
27:3518–3525. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chang H, Qi X, Trieu Y, et al: Multiple
myeloma patients with CKS1B gene amplification have a shorter
progression-free survival post-autologous stem cell
transplantation. Br J Haematol. 135:486–491. 2006. View Article : Google Scholar : PubMed/NCBI
|
